Panelist Bios:
Javad Aman, Ph.D., has over 30 years of experience in the fields of immunology, microbiology, and vaccine development. A highly accomplished scientist, Dr. Aman has published over 100 scientific articles, including many in highly prestigious journals, such as Cell, Science, and Proceeding of the National Academy of Sciences.
Dr. Aman has made important discoveries, such as the receptor for human interleukin-13 as well as small molecule inhibitors and monoclonal antibodies for Ebola and Marburg viruses. In 2007, he founded the research-based company Integrated Biotherapeutics (IBT), where he and his staff develop vaccines and antibody therapeutics for emerging infectious diseases. The company has thus far received nearly $80 million of research funding from the US government and prestigious funding agencies.
Why Vir Biotechnology Stock Is Dropping Today fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
The companies will now wait for more data from this sub-study after an independent panel found that while their drug, VIR-7831, met the criteria to move into the next stage of testing and was safe to use, there was lack of evidence to support how well it would work. Vir and GSK will continue discussions with the U.S. National Institutes of Health, which is backing the late-stage study, to evaluate the next steps to assess the treatment's effectiveness in hospitalized COVID-19 patients, the drugmakers said. Shares of Vir plummeted by more than a quarter to around $41.